This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Bristol-Myers, Sanofi Lower Guidance

Bristol-Myers Squibb (BMY) and marketing partner Sanofi (SNY - Get Report) warned Friday that their earnings this year will take big hits from sales of a generic version of their Plavix blood-thinning drug.

A federal judge Thursday ruled in the two companies' favor by ordering Apotex, the maker of generic Plavix, to halt sales. But the court didn't require Apotex to recall sales or shipments it has made since launching the generic on Aug. 8. Bristol-Myers and Sanofi said they¿re assuming plenty of damage has already been done.

Bristol-Myers said Friday evening that it now expects 2006 earnings of "no less" than 95 cents a share, about 20% less than its previous EPS forecast of $1.15 to $1.25. The company said it didn't know how much generic Plavix Apotex had sold but was assuming enough had hit the market to satisfy all U.S. demand this year.

Earlier Friday, Sanofi had warned that 2006 adjusted EPS would come in about 2% higher than last year's 4.74 euros, or $6.09. The company previously had forecast 12% growth.

Plavix accounted for $3.8 billion of Bristol's sales last year, or 20% of the total. France's Sanofi-Aventis collected sales of $2.45 billion from the drug, or 7.4% of its total revenue.

Thursday's ruling was a preliminary injunction aimed at preventing Apotex from selling more of its drug until a court can take up its patent challenge against Bristol-Myers and Sanofi in January.

Shares of Bristol-Myers ended Friday up $1.20, or 5.5%, at $22.95, buoyed by investor enthusiasm over the injunction. Sanofi ended the session up 42 cents, or 0.9%, at $45.37.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
BMY $60.92 -0.88%
SNY $48.86 -0.02%
AAPL $128.46 -1.50%
FB $78.97 -1.79%
GOOG $558.40 0.53%


DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs